Back to search results

EUS-RFA for Pancreatic Cancer Treatment

This study is testing a treatment for pancreatic cancer (pancreatic ductal adenocarcinoma, or PDAC) that has not responded to initial chemotherapy or cannot be surgically removed. It combines ongoing chemotherapy with a procedure called Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA). EUS-RFA uses a special device (EUSRA RF Electrode) to deliver heat to the tumor. The main goal is to see how many participants can complete the treatment without severe side effects. You may be able to join if you have confirmed PDAC, a tumor at least 1 cm in size, and are receiving second or third-line chemotherapy. This study is currently unclear about its recruitment status and plans to enroll 15 participants.

Study design
This is a single-arm study, meaning all 15 participants will receive the same treatment. The phase of the study is not specified.
What's involved
Participants will continue their second or third-line chemotherapy and receive the EUS-RFA procedure. The study will assess side effects for up to 15 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events for up to 15 weeks after completing therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05723107

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
PHASE1Ages 18+InterventionalTreatment
NYU Langone Health
~15 participants
Updated 2025-11-28 on ClinicalTrials.gov
What's tested:ChemotherapyEndoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0
Measured over Up to Week 15

Conditions

Pancreatic Cancer

Explore related trials

Pancreatic Ductal Adenocarcinoma

NCT05723107

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Tisch Hospital

    New York, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Tamas A. Gonda, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health

Who to contact

Tamas A. Gonda, MD
[email protected]
212-263-3095
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed and histologically confirmed PDAC by biopsy
Axial CT scan or MRI consistent with PDAC with at least 1 cm in greatest diameter
ECOG performance status 0-2
Patients with locally advanced PDAC, who have not responded or progressed on first line chemotherapy, are deemed not resectable based on multidisciplinary review, and show no evidence of distant metastasis
Lesions between 1 - 4cm in size

Exclusion

Patients that show evidence of distant metastasis
Endoscopically non-accessible mass
Pregnant patients
Inability to provide informed consent
Lesions \<1cm, or \>4cm in greatest diameter

What this trial measures

  • Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0Up to Week 15

    Per Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0, Grade III AEs are defined as severe or medically significant but not immediately life-threatening; or hospitalization or prolongation of hospitalization indicated; or disabling; or limiting self care activities of daily living. Grade IV AEs are defined as life-threatening consequences; or urgent intervention indicated.